<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110123</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-18021</org_study_id>
    <secondary_id>EORTC-18021</secondary_id>
    <secondary_id>2004-002245-12</secondary_id>
    <nct_id>NCT00110123</nct_id>
  </id_info>
  <brief_title>Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma</brief_title>
  <official_title>Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fotemustine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Giving the drugs in different ways may kill more tumor cells. It is not yet known whether&#xD;
      giving fotemustine as an intravenous infusion is more effective than giving it as a hepatic&#xD;
      arterial infusion in treating liver metastases.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying intravenous infusion of fotemustine to&#xD;
      see how well it works compared to hepatic arterial infusion of fotemustine in treating&#xD;
      patients with unresectable liver metastases from eye melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare overall survival of patients with surgically incurable or unresectable liver&#xD;
           metastases secondary to uveal melanoma treated with fotemustine administered as an&#xD;
           intravenous infusion vs an intra-arterial hepatic perfusion.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare progression-free survival of patients treated with this drug.&#xD;
&#xD;
        -  Compare the response rate in patients treated with this drug.&#xD;
&#xD;
        -  Compare the duration of objective response in patients treated with this drug.&#xD;
&#xD;
        -  Compare the patterns of progression in patients treated with this drug.&#xD;
&#xD;
        -  Compare treatment-related toxic effects and catheter-related complications in patients&#xD;
           treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified&#xD;
      according to participating center, lactic dehydrogenase level (normal vs abnormal), and WHO&#xD;
      performance status (0 vs 1 vs 2). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive fotemustine IV over 1 hour on days 1, 8, and 15 (induction&#xD;
           course). Beginning on day 50, patients receive maintenance courses of fotemustine IV&#xD;
           over 1 hour every 21 days in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive fotemustine by a 4-hour intra-arterial (IA) hepatic perfusion&#xD;
           on days 1, 8, 15, and 22 (induction course). Beginning on day 57, patients receive&#xD;
           maintenance courses of fotemustine by a 4-hour IA hepatic perfusion every 21 days in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 9 weeks for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 262 patients (131 per treatment arm) will be accrued for this&#xD;
      study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response as assessed by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTCAE v3</measure>
  </secondary_outcome>
  <enrollment type="Actual">171</enrollment>
  <condition>Intraocular Melanoma</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fotemustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isolated perfusion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed liver metastases secondary to uveal melanoma&#xD;
&#xD;
               -  Surgically incurable or unresectable disease&#xD;
&#xD;
          -  No detectable extrahepatic metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST &lt; 5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 5 times ULN&#xD;
&#xD;
          -  Gamma-glutamyltransferase &lt; 5 times ULN&#xD;
&#xD;
          -  Lactic dehydrogenase &lt; 5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  BUN &lt; 1.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled angina pectoris&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No uncontrolled high blood pressure&#xD;
&#xD;
          -  No evolutive intracranial hypertension&#xD;
&#xD;
          -  No other severe cardiac disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active gastroduodenal ulcer&#xD;
&#xD;
          -  No diabetes&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance and follow-up&#xD;
&#xD;
          -  No other uncontrolled severe medical condition&#xD;
&#xD;
          -  No other malignancy within the past 5 years except surgically cured carcinoma in situ&#xD;
             of the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunologic or biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for metastatic disease&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior antineoplastic drugs for metastatic disease&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge Leyvraz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver metastases</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>metastatic intraocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fotemustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

